NSD1

Histone-lysine N-methyltransferase, H3 lysine-36 specific · Q96L73 · NSD1 on Sugi Atlas →

10,269 patent compounds predicted against NSD1, 9,165 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tanshinone I (SCHEMBL244391)	1.00	2/20
Chloroquine (SCHEMBL41313)	0.86	2/20
Hydroxychloroquine (SCHEMBL236192)	0.79	2/20
Tanshinone I (SCHEMBL728081)	0.73	2/20
Hydrochloric Acid (SCHEMBL1041262)	0.66	2/20
SCHEMBL1613020	0.64	2/20
Aminoquinol (SCHEMBL706641)	0.62	2/20
Aminoquinol (SCHEMBL706642)	0.62	2/20
SCHEMBL1147580	0.55	2/20
Juglone (SCHEMBL34185)	0.53	2/20
SCHEMBL74065	0.53	2/20
SCHEMBL1281825	0.53	2/20
Pyrophosphoric Acid (SCHEMBL1611259)	0.51	2/20
SCHEMBL357221	0.43	2/20
SCHEMBL1266791	0.41	2/20
Primaquine (SCHEMBL22207)	1.00	1/20
Primaquine (SCHEMBL22208)	1.00	1/20
Quinacrine (SCHEMBL33693)	1.00	1/20
Plumbagin (SCHEMBL34186)	1.00	1/20
Chloroquine (SCHEMBL40827)	1.00	1/20

Clinical trials — most relevant to NSD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	PHASE2	ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	PHASE1	RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NSD1 binder may also engage these)

Protein	Name	Similarity
Q3V089	—	0.998	Q3V089 →
Q28DZ0	—	0.997	Q28DZ0 →
F6ULY3	—	0.997	F6ULY3 →
Q86XD8	—	0.997	Q86XD8 →
Q8N7Z5	—	0.996	Q8N7Z5 →
E1BC15	—	0.996	E1BC15 →
ASH1L	Histone-lysine N-methyltransferase ASH1L	0.996	landscape →
Q5VWN6	—	0.996	Q5VWN6 →
Q9ULD2	—	0.996	Q9ULD2 →
Q90ZS6	—	0.996	Q90ZS6 →
Q14B71	—	0.996	Q14B71 →
CDCA2	Cell division cycle-associated protein 2	0.996	landscape →
Q6J6J0	—	0.995	Q6J6J0 →
A6QNQ6	—	0.995	A6QNQ6 →
Q92628	—	0.995	Q92628 →
A4IGL8	—	0.995	A4IGL8 →
O60673	—	0.995	O60673 →
Q3TNU4	—	0.995	Q3TNU4 →
Q4V7J0	—	0.995	Q4V7J0 →
E5FYH1	—	0.995	E5FYH1 →
Q9WUF3	—	0.995	Q9WUF3 →
Q6PG16	—	0.994	Q6PG16 →
E5FYH0	—	0.994	E5FYH0 →
Q925H1	—	0.994	Q925H1 →
P56716	—	0.994	P56716 →
Q99MY8	—	0.994	Q99MY8 →
TET1	Methylcytosine dioxygenase TET1	0.994	landscape →
Q6ZV73	—	0.994	Q6ZV73 →
Q9UKL3	—	0.994	Q9UKL3 →
O88491	—	0.994	O88491 →